Walleye Capital
CRNX icon

Walleye Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Walleye Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
38,042
+33,111
+671% +$1.48M 0.01% 1782
2025
Q4 		$230K Buy
+4,931
New +$220K ﹤0.01% 3470
2025
Q3 		– Sell
-190,373
Closed -$5.48M – 4607
2025
Q2 		$5.48M Buy
190,373
+66,391
+54% +$2.05M 0.02% 824
2025
Q1 		$4.16M Sell
123,982
-17,856
-13% -$667K 0.02% 905
2024
Q4 		$7.25M Sell
141,838
-79,108
-36% -$4.43M 0.02% 839
2024
Q3 		$11.3M Sell
220,946
-94,274
-30% -$4.86M 0.02% 623
2024
Q2 		$14.1M Buy
315,220
+73,858
+31% +$3.41M 0.03% 548
2024
Q1 		$11.3M Sell
241,362
-27,726
-10% -$1.08M 0.02% 761
2023
Q4 		$9.57M Sell
269,088
-165,822
-38% -$5.09M 0.02% 692
2023
Q3 		$12.9M Buy
434,910
+121,312
+39% +$2.5M 0.03% 435
2023
Q2 		$5.65M Sell
313,598
-120,097
-28% -$2.39M 0.02% 656
2023
Q1 		$6.97M Buy
433,695
+28,136
+7% +$521K 0.1% 225
2022
Q4 		$7.42M Buy
405,559
+155,545
+62% +$2.74M 0.14% 182
2022
Q3 		$4.91M Buy
250,014
+95,922
+62% +$1.96M 0.09% 235
2022
Q2 		$2.87M Sell
154,092
-29,451
-16% -$588K 0.08% 274
2022
Q1 		$4.03M Buy
183,543
+95,935
+110% +$1.94M 0.11% 198
2021
Q4 		$2.49M Buy
+87,608
New +$2.16M 0.08% 279
2021
Q1 		– Sell
-12,100
Closed -$171 – 1201
2020
Q4 		$171 Buy
+12,100
New +$169K 0.01% 747

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Walleye Capital's CRNX Position: Q1 2026 in Review

Walleye Capital increased its Crinetics Pharmaceuticals (CRNX) stake by 671% in Q1 2026, buying an estimated $1.48M and bringing the position to 38,042 shares worth $1.38M. The position accounts for 0.01% of the portfolio, ranked #1782.

Walleye Capital first reported a position in CRNX in Q4 2020 and has held it in 18 quarters since. The position peaked at $14.1M in Q2 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Walleye Capital held 38,042 shares of Crinetics Pharmaceuticals worth $1.38M as of Q1 2026.
  • Walleye Capital bought 33,111 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $1.48M.
  • Crinetics Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1782 holding.
  • Walleye Capital first reported a position in Crinetics Pharmaceuticals in Q4 2020 and has held it in 18 quarters since.
  • Walleye Capital's Crinetics Pharmaceuticals position peaked at $14.1M in Q2 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.